Abeona Therapeutics (ABEO) Competitors $7.23 +0.12 (+1.69%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.21 -0.02 (-0.28%) As of 08/22/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, ETNB, SNDX, and COGTShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), 89BIO (ETNB), Syndax Pharmaceuticals (SNDX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Syndax Pharmaceuticals Cogent Biosciences Abeona Therapeutics (NASDAQ:ABEO) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has preferable earnings and valuation, ABEO or ARDX? Ardelyx has higher revenue and earnings than Abeona Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M105.93-$63.73M$0.7010.33Ardelyx$333.61M4.41-$39.14M-$0.23-26.57 Do analysts recommend ABEO or ARDX? Abeona Therapeutics presently has a consensus price target of $19.50, suggesting a potential upside of 169.71%. Ardelyx has a consensus price target of $11.50, suggesting a potential upside of 88.22%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ABEO or ARDX? In the previous week, Abeona Therapeutics had 21 more articles in the media than Ardelyx. MarketBeat recorded 25 mentions for Abeona Therapeutics and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.32 beat Abeona Therapeutics' score of 0.49 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ABEO or ARDX? Abeona Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ABEO or ARDX? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ABEO or ARDX more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Abeona Therapeutics' return on equity of 89.05% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% Ardelyx -14.60%-36.57%-13.42% SummaryAbeona Therapeutics beats Ardelyx on 11 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$364.59M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio10.3321.2831.3026.05Price / Sales105.93345.81432.98193.75Price / CashN/A43.1937.7358.48Price / Book2.278.129.536.61Net Income-$63.73M-$54.72M$3.26B$265.65M7 Day Performance1.40%2.62%2.13%2.02%1 Month Performance7.75%2.68%2.80%-0.31%1 Year Performance31.10%10.93%30.68%19.06% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.4362 of 5 stars$7.23+1.7%$19.50+169.7%+41.2%$364.59M$3.50M10.3390News CoverageAnalyst RevisionARDXArdelyx4.3251 of 5 stars$5.81-2.7%$11.50+97.9%+1.0%$1.44B$333.61M-25.2690Positive NewsHROWHarrow3.6368 of 5 stars$38.32-1.3%$64.67+68.8%-5.3%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4379 of 5 stars$14.03-3.4%$31.00+121.0%+5.4%$1.44B$89.15M-28.6390Insider TradeSDGRSchrodinger3.0962 of 5 stars$20.05+3.5%$27.83+38.8%+4.3%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.4369 of 5 stars$29.76-0.2%$31.50+5.8%-35.4%$1.39B$731.97M11.152,028VERAVera Therapeutics3.7452 of 5 stars$21.80+1.2%$63.00+189.0%-42.3%$1.37BN/A-6.0940Positive NewsABCLAbCellera Biologics2.1005 of 5 stars$4.67+1.7%$8.00+71.3%+74.9%$1.37B$28.83M-8.49500ETNB89BIO2.0016 of 5 stars$9.44+2.3%$26.29+178.5%+11.3%$1.37BN/A-2.6140SNDXSyndax Pharmaceuticals4.0799 of 5 stars$15.87+0.8%$38.00+139.4%-20.1%$1.36B$23.68M-4.08110COGTCogent Biosciences3.6242 of 5 stars$12.11+1.9%$18.70+54.4%+24.7%$1.35BN/A-6.8080Positive News Related Companies and Tools Related Companies Ardelyx Alternatives Harrow Alternatives ARS Pharmaceuticals Alternatives Schrodinger Alternatives Amphastar Pharmaceuticals Alternatives Vera Therapeutics Alternatives AbCellera Biologics Alternatives 89BIO Alternatives Syndax Pharmaceuticals Alternatives Cogent Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access